Akashi Therapeutics Inc logo

Akashi Therapeutics Inc

Akashi Therapeutics (formely DART Therapeutics) is a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy and other rare pediatric diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.akashirx.com
Founded2010
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
245 First Street, 18th Floor, MA 02142
Cambridge
United States
Email
Contact Number
617-431-7250

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/akashi-therapeutics-inc-” connections=”true” suffix=””]

In 2014, Akashi acquired global rights to GsMTx-4, a peptide developed by Tonus Therapeutics, to address calcium level imbalance in muscle, a critical issue in DMD contributing to loss of function and other associated pathologies.

In Jan 2016, Akashi signed a $100 Mn partnership with GrÈnenthal Group for a global drug development of HT-100, for the reduction of fibrosis and inflammation, and promotion of healthy muscle fiber regeneration in DMD.

In 2014, the Muscular Dystrophy Association (MDA) made an investment in Akashi, through the MDA Venture Philanthropy program to fund clinical development of HT-100.